Results 111 to 120 of about 203,911 (301)
High humidity environment increases FBG by impairing the intestinal barrier
IntroductionClimate and environmental changes pose significant threats to human metabolic health; however, the specific effects of individual environmental factors on metabolic diseases remain poorly understood. This study aimed to investigate the impact
Yao Wang +19 more
doaj +1 more source
Frailty and Cardiovascular Events as Determined by Body Composition: A Systematic Review
Frailty phenotypes and risk of cardiovascular disease. Sarcopenic obese phenotype is associated with increased prevalence of cardiovascular risk factors and progression of metabolic syndrome, leading to cardiovascular events and cardiovascular mortality, while the Anorexic malnourished phenotype is associated with reduced prevalence of cardiovascular ...
Ishleen Oberoi +5 more
wiley +1 more source
BackgroundHormonal and metabolic responses to high protein intake are not well understood. The aims of this study were to compare the metabolic and hormonal responses to isocaloric intakes of whey protein alone versus carbohydrate alone. Additionally, we
Matthieu Clauss +6 more
doaj +1 more source
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves +8 more
wiley +1 more source
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley +1 more source
Plamen Kozlovski,1 Vaishali Bhosekar,2 James E Foley3 1Novartis Pharma AG, Basel, Switzerland; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA Introduction: Dipeptidyl peptidase-4 (DPP ...
Kozlovski P, Bhosekar V, Foley JE
doaj
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
The rates of increase in the incidence of type 2 diabetes mellitus (T2DM) and obesity in the world are steadily increasing and exceed even the wildest forecasts, which forces specialists to seek, develop and implement more effective therapeutic methods ...
Marina V. Shestakova, Roza O. Bashlykova
doaj +1 more source
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson +4 more
wiley +1 more source
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon +10 more
wiley +1 more source
Ultrastructural features of pancreatic islets in rats with experimental pathology
In type 1 diabetes mellitus, the primary pathological alterations in the endocrine apparatus arise from the progressive loss of beta-cells, whereas beta-cell dysfunction is the key pathogenic factor in type 2 diabetes mellitus.
T. V. Ivanenko +2 more
doaj +1 more source

